<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03702491</url>
  </required_header>
  <id_info>
    <org_study_id>XJiang</org_study_id>
    <nct_id>NCT03702491</nct_id>
  </id_info>
  <brief_title>Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma</brief_title>
  <official_title>A Single-center Open, Randomized, Controlled Study to Compare the Apapitatin Combined With SOX and SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Hepatobiliary Surgery Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eastern Hepatobiliary Surgery Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Single-center Open, Randomized, Controlled Study to Compare the Apapitatin Mesylate
      Combined With SOX Regimen and SOX Regimen for Palliative Adjuvant Chemotherapy in Patients
      With Advanced Gallbladder Carcinoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to observe and evaluate the progression-free survival time (PFS),
      overall survival time (OS) and safety of patients with advanced Gallbladder Carcinoma treated
      with apatinib mesylate combined with SOX
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2018</start_date>
  <completion_date type="Anticipated">August 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 10, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>12 month after first treatment</time_frame>
    <description>progression-free survival</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Gallbladder Carcinoma</condition>
  <arm_group>
    <arm_group_label>Apatinib with SOX(Tegafur,Oxaliplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients 3-4 weeks after surgery, the SOX regimen was given palliative adjuvant chemotherapy for 6-8 cycles, then followed by the second cycle combined with the treatment of apatinib mesylate and the monotherapy maintenance of apatinib mesylate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOX( Tegafur,Oxaliplatin)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3-4 weeks after operation, 6-8 cycles of adjuvant chemotherapy with simple SOX protocol were given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Three to four weeks after surgery, the SOX regimen was given palliative adjuvant chemotherapy for 6-8 cycles, then followed by the second cycle combined with the treatment of apatinib mesylate and the monotherapy maintenance of apatinib mesylate</description>
    <arm_group_label>Apatinib with SOX(Tegafur,Oxaliplatin)</arm_group_label>
    <other_name>Tegafur</other_name>
    <other_name>Oxaliplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegafur</intervention_name>
    <description>3-4 weeks after operation, 6-8 cycles of adjuvant chemotherapy with simple SOX protocol were given.</description>
    <arm_group_label>SOX( Tegafur,Oxaliplatin)</arm_group_label>
    <other_name>Oxaliplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ages 18 to 75

          2. UICC/AJCC gallbladder TNM staging (The eighth edition), Ⅲ B - ⅣB (excluding M1)
             postoperative pathological diagnosis of gallbladder carcinoma;Patients confirmed to
             have undergone R1/R2 cholecystectomy or palliative surgery;

          3. The primary treatment is surgical resection or potentially resectable cholecystic
             carcinoma without other treatment

          4. ECOG performance status ≤1

          5. The liver and kidney function meets the following conditions： BIL&lt;3 normal value upper
             limit (ULN)；ALT and AST&lt; 2.5 xULN;Serum Cr≤ 1xULN,Clearance rate of endogenous
             creatinine＞50ml/min（Cockcroft-Gault）;

          6. Other test rooms meet the following requirements:

             Hemoglobin ≥ 90 g/L (no blood transfusion within 14 days)；Neutrophilic granulocyte
             count &gt; 1.5x109 /L;The platelet count ≥ 80 x 10 ^ 9/L;

          7. Estimated life expectancy &gt; 3 months.

          8. Before the enrollment, the heart function is good. There is no episode of myocardial
             infarction within half a year. For example, if you have hypertension or coronary heart
             disease, you should ensure that it is within the controllable range.

          9. Patient able and willing to provide written informed consent and to comply with the
             study protocol and Good compliance, with follow-up.

        Exclusion Criteria:

          1. Non gallbladder carcinoma

          2. Significant clinical bleeding symptoms or a clear tendency to bleed occurred within
             the first month of randomization, such as cough/hemoptysis of 2.5ml or more,
             gastrointestinal bleeding, esophagogastric varices at risk of bleeding, hemorrhagic
             gastric ulcer, etc.

          3. Other topical treatments during the study (including intraperitoneal chemotherapy,
             radiotherapy, etc.)

          4. Pregnant or lactating women；

          5. Those who suffer from high blood pressure and cannot be treated to the normal range by
             antihypertensive drugs；

          6. HIV infection or the presence of AIDS-related diseases, or severe acute and chronic
             diseases;

          7. Have grade II or higher myocardial ischemia or myocardial infarction、Poorly controlled
             arrhythmia；

          8. Severe active infections；

          9. There are secondary malignant tumors or other tumors within 3 years before the start
             of the study and there is metastasis of the brain or meninges.

         10. Researchers believe that their compliance is poor

         11. There are contraindications for Apatinib and S-1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>xiao qing Jiang, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>700 Moyu Road North, Jiading District,Eastern Hepatobiliary Surgery Hospital, Shanghai, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>xiao qing Jiang, professor</last_name>
    <phone>13801603438</phone>
    <phone_ext>13801603438</phone_ext>
    <email>Jxq1225@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>xiao qing xiao qing Jiang</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xiao q xiao qing Jiang</last_name>
      <phone>13801603438</phone>
      <phone_ext>13801603438</phone_ext>
      <email>Jxq1225@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>October 7, 2018</study_first_submitted>
  <study_first_submitted_qc>October 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2018</study_first_posted>
  <last_update_submitted>October 9, 2018</last_update_submitted>
  <last_update_submitted_qc>October 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eastern Hepatobiliary Surgery Hospital</investigator_affiliation>
    <investigator_full_name>Xiaoqing Jiang</investigator_full_name>
    <investigator_title>Professor Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Apatinib</mesh_term>
    <mesh_term>Tegafur</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

